Cel-Sci Corporation (CVM) Shares are Down -28.24%

Cel-Sci Corporation (CVM) : During the past 4 weeks, traders have been relatively bearish on Cel-Sci Corporation (CVM), hence the stock is down -28.69% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -28.35% relative to the S&P 500. The 4-week change in the price of the stock is -29.07% and the stock has fallen -28.24% in the past 1 week.

The stock has recorded a 20-day Moving Average of 23.62% and the 50-Day Moving Average is 32.45%.The 200 Day SMA reached 37.85%

Cel-Sci

Cel-Sci Corporation (NYSEMKT:CVM): After opening at $0.2765, the stock dipped to an intraday low of $0.2725 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.3192 and the buying power remained strong till the end. The stock closed at $0.305 for the day, a gain of 10.51% for the day session. The total traded volume was 1,431,229. The stocks close on the previous trading day was $0.305.

CEL-SCI Corporation is a biotechnology company. The Company is engaged in the research and development of drugs and vaccines. The Company researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Companys product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine. The Companys lead investigational therapy Multikine is in the Phase III clinical trial against head and neck cancer, for which the Company has received Orphan Drug Status from the United States Food and Drug Administration. LEAPS is the Companys pre-clinical technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.